Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2009 3
2010 3
2011 1
2012 1
2014 2
2015 2
2016 5
2017 2
2018 2
2019 3
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

23 results
Results by year
Filters applied: . Clear all
Page 1
Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition.
Dhir T, Schultz CW, Jain A, Brown SZ, Haber A, Goetz A, Xi C, Su GH, Xu L, Posey J 3rd, Jiang W, Yeo CJ, Golan T, Pishvaian MJ, Brody JR. Dhir T, et al. Mol Cancer Res. 2019 Oct;17(10):2029-2041. doi: 10.1158/1541-7786.MCR-19-0589. Epub 2019 Aug 5. Mol Cancer Res. 2019. PMID: 31383722 Free PMC article.
Accordingly, siRNA oligonucleotides targeted against HuR, YAP1, and their common target cyclin D1, validated the synergy studies. ...PDAC cells chronically cultured with abemaciclib displayed a reduction in cellular growth rates (GR) and coresistance to gemcitabine
Accordingly, siRNA oligonucleotides targeted against HuR, YAP1, and their common target cyclin D1, validated the synergy studies. ... …
Four-weekly Low-dose Gemcitabine and Paclitaxel in Patients With Platinum-resistant Urothelial Cancer and Performance Status 2/3.
Araki K, Miyata Y, Nakamura Y, Mukae Y, Otsubo A, Yuno T, Mitsunari K, Matsuo T, Ohba K, Sakai H. Araki K, et al. In Vivo. 2019 Nov-Dec;33(6):2217-2224. doi: 10.21873/invivo.11725. In Vivo. 2019. PMID: 31662559 Free PMC article.
The aim of this study was to assess the safety and usefulness of combined therapy with low-dose gemcitabine and paclitaxel every 4 weeks. PATIENTS AND METHODS: Thirty patients were treated with gemcitabine (700 mg/m(2) on day 1) and paclitaxel (70 mg/m(2) on day 1) …
The aim of this study was to assess the safety and usefulness of combined therapy with low-dose gemcitabine and paclitaxel every 4 we …
Crabp2 Promotes Metastasis of Lung Cancer Cells via HuR and Integrin beta1/FAK/ERK Signaling.
Wu JI, Lin YP, Tseng CW, Chen HJ, Wang LH. Wu JI, et al. Sci Rep. 2019 Jan 29;9(1):845. doi: 10.1038/s41598-018-37443-4. Sci Rep. 2019. PMID: 30696915 Free PMC article.
Knockdown of Crabp2 decreased migration, invasion, anoikis resistance, and in vivo metastasis. Crabp2 was co-immunoprecipitated with HuR, and overexpression of Crabp2 increased HuR levels, which promoted integrin beta1/FAK/ERK signaling. ...Knockdown of Crabp2 furth …
Knockdown of Crabp2 decreased migration, invasion, anoikis resistance, and in vivo metastasis. Crabp2 was co-immunoprecipitated with HuR
HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
Jakstaite A, Maziukiene A, Silkuniene G, Kmieliute K, Gulbinas A, Dambrauskas Z. Jakstaite A, et al. World J Gastroenterol. 2015 Dec 14;21(46):13004-19. doi: 10.3748/wjg.v21.i46.13004. World J Gastroenterol. 2015. PMID: 26675757 Free PMC article.
AIM: To investigate the expression of HuR in pancreatic ductal adenocarcinoma (PDA) and to assess the effects of HuR silencing on the expression of cyclooxygenase-2 (COX-2) and heme oxygenase-1 (HO-1) and the in vitro response to gemcitabine (GEM) treatment i …
AIM: To investigate the expression of HuR in pancreatic ductal adenocarcinoma (PDA) and to assess the effects of HuR silencing …
Cytoplasmic Hu-Antigen R (HuR) Expression is Associated with Poor Survival in Patients with Surgically Resected Cholangiocarcinoma Treated with Adjuvant Gemcitabine-Based Chemotherapy.
Toyota K, Murakami Y, Kondo N, Uemura K, Nakagawa N, Takahashi S, Sueda T. Toyota K, et al. Ann Surg Oncol. 2018 May;25(5):1202-1210. doi: 10.1245/s10434-018-6392-y. Epub 2018 Feb 28. Ann Surg Oncol. 2018. PMID: 29492748
BACKGROUND: Hu-antigen R (HuR) is an RNA-binding protein that regulates the stability, translation, and nucleus-to-cytoplasm translocation of messenger RNAs (mRNAs). OBJECTIVE: The aim of this study was to investigate the prognostic significance of HuR
BACKGROUND: Hu-antigen R (HuR) is an RNA-binding protein that regulates the stability, translation, and nucleus-to-cyto …
Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer.
Miyata Y, Mitsunari K, Akihiro A, Watanabe SI, Matsuo T, Ohba K, Sakai H. Miyata Y, et al. Oncol Lett. 2017 Feb;13(2):811-818. doi: 10.3892/ol.2016.5484. Epub 2016 Dec 12. Oncol Lett. 2017. PMID: 28356963 Free PMC article.
Although no standard regime for the treatment of CDDP-resistant UC has been established, GEM-based regimens are frequently used in these patients. In other types of cancer, human antigen R (HuR) status in cancer cells is closely associated with patient …
Although no standard regime for the treatment of CDDP-resistant UC has been established, GEM-based regimens are frequently used in these pat …
HuR's role in gemcitabine efficacy: an exception or opportunity?
Brody JR, Gonye GE. Brody JR, et al. Wiley Interdiscip Rev RNA. 2011 May-Jun;2(3):435-44. doi: 10.1002/wrna.62. Epub 2010 Nov 30. Wiley Interdiscip Rev RNA. 2011. PMID: 21957028 Review.
Highlighting an alternative to this 'genome-centric' approach, this review will further explore an underappreciated mechanism of gene expression regulation, posttranscription mRNA:protein interactions. A key molecule involved in this mode of gene regulation is HuR and we h …
Highlighting an alternative to this 'genome-centric' approach, this review will further explore an underappreciated mechanism of gene expres …
Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Oba A, Ban D, Kirimura S, Akahoshi K, Mitsunori Y, Matsumura S, Ochiai T, Kudo A, Tanaka S, Minoru T. Oba A, et al. J Hepatobiliary Pancreat Sci. 2016 Aug;23(8):480-8. doi: 10.1002/jhbp.366. Epub 2016 Jun 23. J Hepatobiliary Pancreat Sci. 2016. PMID: 27247050
We evaluated the correlation between treatment outcomes and the expressions of intratumoral human antigen R (HuR), human equilibrative nucleoside transporter 1 (hENT1), thymidylate synthetase (TS) and dihydropyrimidine dehydrogenase (DPD). ...Mo …
We evaluated the correlation between treatment outcomes and the expressions of intratumoral human antigen R (HuR
Establishment and characterization of a new human gallbladder carcinoma cell line.
Sekine S, Shimada Y, Nagata T, Moriyama M, Omura T, Yoshioka I, Hori R, Matsui K, Sawada S, Okumura T, Yoshida T, Tsukada K. Sekine S, et al. Anticancer Res. 2012 Aug;32(8):3211-8. Anticancer Res. 2012. PMID: 22843894
This cell line was transplantable to nude mice. We characterized the sensitivity of TYGBK-1 to gemcitabine. We also examined the association of two gemcitabine-related genes (deoxycytidine kinase, dCK, and Hu antigen R, HuR). Among four GBC cell …
This cell line was transplantable to nude mice. We characterized the sensitivity of TYGBK-1 to gemcitabine. We also examined the asso …
Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy.
Huang YH, Peng W, Furuuchi N, DuHadaway JB, Jimbo M, Pirritano A, Dunton CJ, Daum GS, Leiby BE, Brody JR, Sawicki JA. Huang YH, et al. Oncotarget. 2016 Apr 19;7(16):21812-24. doi: 10.18632/oncotarget.7840. Oncotarget. 2016. PMID: 26943573 Free PMC article.
We immunohistochemically stained sections of 31 surgically-debulked chemo-naive ovarian tumors for HuR and scored the degree of HuR cytoplasmic staining. We found no correlation between HuR intracellular localization in tumor sections and progression free sur …
We immunohistochemically stained sections of 31 surgically-debulked chemo-naive ovarian tumors for HuR and scored the degree of Hu
23 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page